全文获取类型
收费全文 | 91379篇 |
免费 | 29926篇 |
国内免费 | 1056篇 |
专业分类
耳鼻咽喉 | 2366篇 |
儿科学 | 2470篇 |
妇产科学 | 2216篇 |
基础医学 | 1855篇 |
口腔科学 | 4965篇 |
临床医学 | 25386篇 |
内科学 | 23305篇 |
皮肤病学 | 3116篇 |
神经病学 | 11729篇 |
特种医学 | 3456篇 |
外科学 | 17203篇 |
综合类 | 95篇 |
现状与发展 | 40篇 |
预防医学 | 12836篇 |
眼科学 | 2056篇 |
药学 | 792篇 |
中国医学 | 5篇 |
肿瘤学 | 8470篇 |
出版年
2024年 | 100篇 |
2023年 | 4999篇 |
2022年 | 1049篇 |
2021年 | 2603篇 |
2020年 | 5245篇 |
2019年 | 1892篇 |
2018年 | 6740篇 |
2017年 | 7225篇 |
2016年 | 7792篇 |
2015年 | 7867篇 |
2014年 | 10224篇 |
2013年 | 11856篇 |
2012年 | 3358篇 |
2011年 | 3103篇 |
2010年 | 6583篇 |
2009年 | 8899篇 |
2008年 | 3138篇 |
2007年 | 2064篇 |
2006年 | 3256篇 |
2005年 | 1817篇 |
2004年 | 1227篇 |
2003年 | 928篇 |
2002年 | 862篇 |
2001年 | 1774篇 |
2000年 | 1096篇 |
1999年 | 1640篇 |
1998年 | 2031篇 |
1997年 | 1829篇 |
1996年 | 1920篇 |
1995年 | 1660篇 |
1994年 | 1062篇 |
1993年 | 894篇 |
1992年 | 725篇 |
1991年 | 616篇 |
1990年 | 493篇 |
1989年 | 503篇 |
1988年 | 486篇 |
1987年 | 354篇 |
1986年 | 342篇 |
1985年 | 284篇 |
1984年 | 243篇 |
1983年 | 292篇 |
1982年 | 219篇 |
1981年 | 191篇 |
1980年 | 115篇 |
1978年 | 119篇 |
1977年 | 114篇 |
1976年 | 83篇 |
1974年 | 70篇 |
1972年 | 70篇 |
排序方式: 共有10000条查询结果,搜索用时 203 毫秒
41.
Cheryl L. Rock PhD RD Cynthia A. Thomson PhD RD Kristen R. Sullivan MS MPH Carol L. Howe MD MLS Lawrence H. Kushi ScD Bette J. Caan DrPH Marian L. Neuhouser PhD RD Elisa V. Bandera MD PhD Ying Wang PhD Kimberly Robien PhD RD Karen M. Basen-Engquist PhD MPH Justin C. Brown PhD Kerry S. Courneya PhD Tracy E. Crane PhD RDN David O. Garcia PhD FACSM Barbara L. Grant MS RDN CSO FAND Kathryn K. Hamilton MA RDN CSO CDN FAND Sheri J. Hartman PhD Stacey A. Kenfield ScD Maria Elena Martinez PhD Jeffrey A. Meyerhardt MD MPH Larissa Nekhlyudov MD MPH Linda Overholser MD Alpa V. Patel PhD Bernardine M. Pinto PhD Mary E. Platek PhD RD CDN Erika Rees-Punia PhD MPH Colleen K. Spees PhD MEd RD LD FAND Susan M. Gapstur PhD Marjorie L. McCullough ScD RD 《CA: a cancer journal for clinicians》2022,72(3):230-262
The overall 5-year relative survival rate for all cancers combined is now 68%, and there are over 16.9 million survivors in the United States. Evidence from laboratory and observational studies suggests that factors such as diet, physical activity, and obesity may affect risk for recurrence and overall survival after a cancer diagnosis. The purpose of this American Cancer Society guideline is to provide evidence-based, cancer-specific recommendations for anthropometric parameters, physical activity, diet, and alcohol intake for reducing recurrence and cancer-specific and overall mortality. The audiences for this guideline are health care providers caring for cancer survivors as well as cancer survivors and their families. The guideline is intended to serve as a resource for informing American Cancer Society programs, health policy, and the media. Sources of evidence that form the basis of this guideline are systematic literature reviews, meta-analyses, pooled analyses of cohort studies, and large randomized clinical trials published since 2012. Recommendations for nutrition and physical activity during cancer treatment, informed by current practice, large cancer care organizations, and reviews of other expert bodies, are also presented. To provide additional context for the guidelines, the authors also include information on the relationship between health-related behaviors and comorbidities, long-term sequelae and patient-reported outcomes, and health disparities, with attention to enabling survivors' ability to adhere to recommendations. Approaches to meet survivors' needs are addressed as well as clinical care coordination and resources for nutrition and physical activity counseling after a cancer diagnosis. 相似文献
42.
43.
Naveen Pemmaraju MD Jacqueline S. Garcia MD Andrew Perkins MBBS PhD Jason G. Harb PhD Andrew J. Souers PhD Michael E. Werner PhD Christopher M. Brown PhD Francesco Passamonti MD 《Cancer》2023,129(22):3535-3545
Myelofibrosis is a heterogeneous myeloproliferative neoplasm characterized by chronic inflammation, progressive bone marrow failure, and hepatosplenic extramedullary hematopoiesis. Treatments like Janus kinase inhibitor monotherapy (e.g., ruxolitinib) provide significant spleen and symptom relief but demonstrate limited ability to lead to a durable disease modification. There is an urgent unmet medical need for treatments with a novel mechanism of action that can modify the underlying pathophysiology and affect the disease course of myelofibrosis. This review highlights the role of B-cell lymphoma (BCL) protein BCL-extra large (BCL-XL) in disease pathogenesis and the potential role that navitoclax, a BCL-extra large/BCL-2 inhibitor, may have in myelofibrosis treatment. 相似文献
44.
45.
46.
Yan Gao MD Yizhen Liu MD PhD Yafei Wang MD Qingyuan Zhang MD Depei Wu MD Xu Ye MD Jianqiu Wu MD Wei Xu MD Jianfeng Zhou MD Yu Yang MD Hong Cen MD Feng Zhang MD Ying Xiang MD Xiaoqiong Tang MD Kaiyang Ding MD JinYing Lin MD Lei Ma MD Shunqing Wang MD Hao Yu MD Yang Zhao MD Bin Song MD Fangfang Lv MD Huiqiang Huang MD 《Cancer》2023,129(4):551-559
47.
48.
Objective
The aim of the study was to estimate the effect of the state-based reinsurance programs through the section 1332 State Innovation Waivers on health insurance marketplace premiums and insurer participation.Data Source
2015 to 2022 Robert Wood Johnson Foundation Health Insurance Exchange Compare Datasets.Study Design
An event study difference-in-differences (DD) model separately for each year of implementation and a synthetic control method (SCM) are used to estimate year-by-year effects following program implementation.Data Collection/Extraction Methods
Not applicable.Principal Findings
Reinsurance programs were associated with a decline in premiums in the first year of implementation by 10%–13%, 5%–19%, and 11%–17% for bronze, silver, and gold plans (p < 0.05). There is a trend of sustained declines especially for states that implemented their programs in 2019 and 2020. The SCM analyses suggest some effect heterogeneity across states but also premium declines across most states. There is no evidence that reinsurance programs affected insurer participation.Conclusion
State-based reinsurance programs have the potential to improve the affordability of health insurance coverage. However, reinsurance programs do not appear to have had an effect on insurer participation, highlighting the need for policy makers to consider complementary strategies to encourage insurer participation. 相似文献49.